Table 3 Exploratory biomarker endpoints in the evoke and evoke+ trials

Main study

Blood

Change in NfL level

Neuroaxonal damage

Baseline to week 104

Change in GFAP level

Astrogliosis

Change in p-tau181 level

Amyloid burden

CSF sub-study

CSF

Change in sTREM2 level

Neuroinflammation

Baseline to week 78

Change in MCP1/CCL2 level^a

Change in YKL-40 level

Change in GFAP level

Change in IL-8 level^a

Change in IL-6 level^a

Change in SMOC1 level^a

Change in osteopontin level^a

Change in IL-1β level^a

Change in IP-10/CXCL10 level

Change in IL-1 receptor antagonist level^a

Change in IL-18 level^a

Change in NfL level

Neurodegeneration

Change in neurogranin level

Change in total tau level

Change in amyloid β 42/40 level

Alzheimer’s disease

Change in p-tau181 level

Change in sPDGFRβ level^a

Change in CSF/serum albumin ratio^b

Vascular health/blood–brain barrier integrity

Change in isoprostanes level^a

Change in 8-OHdG level^a

Oxidative stress

Change in complement factor 3 level^a

Change in complement factor 4 level^a

Complement system

Semaglutide concentration in CSF^a

Other

Week 78